Vericel Corporation
VCELHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports. Valued at $2.06B, VCEL is a mid-cap name in its sector. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Market Cap
$2.06B
Beta
1.05
P/E (TTM)
83.73
P/E (Fwd)
47.51
EPS (TTM)
$0.48
EPS (Fwd)
$0.85
ROE
7.2%
ROA
2.4%
Cash
$162.5M
Total Debt
$93.1M
Free CF
$55.5M
52W Change
18.9%
Annual Financials
Cash vs Debt
Where VCEL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, VCEL finished 5.97% above its 150-day moving average ($38.22) and 6.19% above its 200-day moving average ($38.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VCEL overbought or oversold?
At the September 2, 2026 close, VCEL's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $162.5M in cash comfortably exceeding the $93.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $55.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 7.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.4% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $164.4M (2022) to $276.3M (2025), reflecting a 68% increase over the period.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VCEL.